alhydrogel injectable (AD04) / ADvantage Therap 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   1 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alhydrogel injectable (AD04) / ADvantage Therap
2022-003532-73: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE Multicentrické, randomizované, placebom-kontrolované, dvojito zaslepené klinické skúšanie fázy 2b na stanovenie bezpečnosti a účinnosti produktu AD04 u pacientov s včasnou Alzheimerovou chorobou – ADVANCE

Not yet recruiting
2
122
Europe, RoW
AD04, AD04, Solution for injection
ADvantage Therapeutics GmbH, ADvantage Therapeutics GmbH
early Alzheimer’s disease, early Alzheimer’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 

Download Options